Pharmacological treatment of lower urinary tract symptoms in men: implementation of recommendations in clinical practice

Introducing a consensus on pharmacological treatment of male LUTs to be applied to Urology Primary Care. EVIDENCE COMPILATION: The consensus has been created by an expert committee based on the latest recommendations by the European and American Guides for male LUTs treatment. Also, a bibliographic...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Actas urologicas españolas 2013-06, Vol.37 (6), p.330-337
Hauptverfasser: Esteban, M, Castro, D M
Format: Artikel
Sprache:eng ; spa
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 337
container_issue 6
container_start_page 330
container_title Actas urologicas españolas
container_volume 37
creator Esteban, M
Castro, D M
description Introducing a consensus on pharmacological treatment of male LUTs to be applied to Urology Primary Care. EVIDENCE COMPILATION: The consensus has been created by an expert committee based on the latest recommendations by the European and American Guides for male LUTs treatment. Also, a bibliographic review of the latest advances in the therapeutical approach to these patients has been carried out. Although the prevalence of both LUTs and overactive bladder is high, and its impact on the quality of life and social cost have been widely described, the number of patients treated is low. On the other hand, current clinical practice doesn't necessarily match the Guides and for this reason false perceptions of the available treatments circulate. For instance, men with storage LUTS are often treated inadequately with α-blockers or 5-α-reductase inhibitors due to underlying obstructive disorders. However, it is known that the incidence of real obstruction tends to be low. Current evidence, though limited, shows that antimuscarinic drugs may be used safely by men with LUTs, and are not associated with an increase in the prevalence of high urinary retention. We propose an algorithm for the management of male LUTs in which various levels of clinical evaluation are shown for a specific diagnose, as well as for choosing the most appropriate treatment.
doi_str_mv 10.1016/j.acuro.2012.05.007
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_1445912824</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1445912824</sourcerecordid><originalsourceid>FETCH-LOGICAL-p141t-9f920ff143ec917075ce68f639431806b96fb2eb5c9f8250e18bbcfcffe581a33</originalsourceid><addsrcrecordid>eNo1kE9LxDAUxIMg7rr6CQTJ0UtrkjZt4k3Ef7CgBz0vafZFsyRNTVJ0v73ddT09mDfzgxmELigpKaHN9aZUeoyhZISykvCSkPYIzWkjZdFKQWboNKUNIayuRHuCZoxJLjlt5ujn9VNFr3Rw4cNq5XCOoLKHPuNgsAvfEPEYba_idnopnXHa-iEHn7Dt8eS7wdYPDnYJlW3od7EIOvhJWe-VvVM72-_5ww5iNZyhY6NcgvPDXaD3h_u3u6di-fL4fHe7LAZa01xIIxkxhtYVaElb0nINjTBNJeuKCtJ0sjEdg45raQTjBKjoOm20McAFVVW1QFd_3CGGrxFSXnmbNDineghjWtG65pIyMU2zQJcH69h5WK-GaP3Ue_W_VvULfaBvHw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1445912824</pqid></control><display><type>article</type><title>Pharmacological treatment of lower urinary tract symptoms in men: implementation of recommendations in clinical practice</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Esteban, M ; Castro, D M</creator><creatorcontrib>Esteban, M ; Castro, D M ; comité científico</creatorcontrib><description>Introducing a consensus on pharmacological treatment of male LUTs to be applied to Urology Primary Care. EVIDENCE COMPILATION: The consensus has been created by an expert committee based on the latest recommendations by the European and American Guides for male LUTs treatment. Also, a bibliographic review of the latest advances in the therapeutical approach to these patients has been carried out. Although the prevalence of both LUTs and overactive bladder is high, and its impact on the quality of life and social cost have been widely described, the number of patients treated is low. On the other hand, current clinical practice doesn't necessarily match the Guides and for this reason false perceptions of the available treatments circulate. For instance, men with storage LUTS are often treated inadequately with α-blockers or 5-α-reductase inhibitors due to underlying obstructive disorders. However, it is known that the incidence of real obstruction tends to be low. Current evidence, though limited, shows that antimuscarinic drugs may be used safely by men with LUTs, and are not associated with an increase in the prevalence of high urinary retention. We propose an algorithm for the management of male LUTs in which various levels of clinical evaluation are shown for a specific diagnose, as well as for choosing the most appropriate treatment.</description><identifier>EISSN: 1699-7980</identifier><identifier>DOI: 10.1016/j.acuro.2012.05.007</identifier><identifier>PMID: 22959516</identifier><language>eng ; spa</language><publisher>Spain</publisher><subject>5-alpha Reductase Inhibitors - adverse effects ; 5-alpha Reductase Inhibitors - therapeutic use ; Adrenergic alpha-Antagonists - adverse effects ; Adrenergic alpha-Antagonists - therapeutic use ; Algorithms ; Deamino Arginine Vasopressin - adverse effects ; Deamino Arginine Vasopressin - therapeutic use ; Drug Interactions ; Drug Therapy, Combination ; Humans ; Hyponatremia - chemically induced ; Lower Urinary Tract Symptoms - classification ; Lower Urinary Tract Symptoms - diagnosis ; Lower Urinary Tract Symptoms - drug therapy ; Male ; Muscarinic Antagonists - adverse effects ; Muscarinic Antagonists - therapeutic use ; Prostatism - diagnosis ; Prostatism - drug therapy ; Prostatism - surgery ; Severity of Illness Index ; Sodium Potassium Chloride Symporter Inhibitors - adverse effects ; Sodium Potassium Chloride Symporter Inhibitors - therapeutic use ; Urinary Retention - chemically induced</subject><ispartof>Actas urologicas españolas, 2013-06, Vol.37 (6), p.330-337</ispartof><rights>Copyright © 2012 AEU. Published by Elsevier Espana. All rights reserved.</rights><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>309,310,314,776,780,785,786,23909,23910,25118,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/22959516$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Esteban, M</creatorcontrib><creatorcontrib>Castro, D M</creatorcontrib><creatorcontrib>comité científico</creatorcontrib><title>Pharmacological treatment of lower urinary tract symptoms in men: implementation of recommendations in clinical practice</title><title>Actas urologicas españolas</title><addtitle>Actas Urol Esp</addtitle><description>Introducing a consensus on pharmacological treatment of male LUTs to be applied to Urology Primary Care. EVIDENCE COMPILATION: The consensus has been created by an expert committee based on the latest recommendations by the European and American Guides for male LUTs treatment. Also, a bibliographic review of the latest advances in the therapeutical approach to these patients has been carried out. Although the prevalence of both LUTs and overactive bladder is high, and its impact on the quality of life and social cost have been widely described, the number of patients treated is low. On the other hand, current clinical practice doesn't necessarily match the Guides and for this reason false perceptions of the available treatments circulate. For instance, men with storage LUTS are often treated inadequately with α-blockers or 5-α-reductase inhibitors due to underlying obstructive disorders. However, it is known that the incidence of real obstruction tends to be low. Current evidence, though limited, shows that antimuscarinic drugs may be used safely by men with LUTs, and are not associated with an increase in the prevalence of high urinary retention. We propose an algorithm for the management of male LUTs in which various levels of clinical evaluation are shown for a specific diagnose, as well as for choosing the most appropriate treatment.</description><subject>5-alpha Reductase Inhibitors - adverse effects</subject><subject>5-alpha Reductase Inhibitors - therapeutic use</subject><subject>Adrenergic alpha-Antagonists - adverse effects</subject><subject>Adrenergic alpha-Antagonists - therapeutic use</subject><subject>Algorithms</subject><subject>Deamino Arginine Vasopressin - adverse effects</subject><subject>Deamino Arginine Vasopressin - therapeutic use</subject><subject>Drug Interactions</subject><subject>Drug Therapy, Combination</subject><subject>Humans</subject><subject>Hyponatremia - chemically induced</subject><subject>Lower Urinary Tract Symptoms - classification</subject><subject>Lower Urinary Tract Symptoms - diagnosis</subject><subject>Lower Urinary Tract Symptoms - drug therapy</subject><subject>Male</subject><subject>Muscarinic Antagonists - adverse effects</subject><subject>Muscarinic Antagonists - therapeutic use</subject><subject>Prostatism - diagnosis</subject><subject>Prostatism - drug therapy</subject><subject>Prostatism - surgery</subject><subject>Severity of Illness Index</subject><subject>Sodium Potassium Chloride Symporter Inhibitors - adverse effects</subject><subject>Sodium Potassium Chloride Symporter Inhibitors - therapeutic use</subject><subject>Urinary Retention - chemically induced</subject><issn>1699-7980</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo1kE9LxDAUxIMg7rr6CQTJ0UtrkjZt4k3Ef7CgBz0vafZFsyRNTVJ0v73ddT09mDfzgxmELigpKaHN9aZUeoyhZISykvCSkPYIzWkjZdFKQWboNKUNIayuRHuCZoxJLjlt5ujn9VNFr3Rw4cNq5XCOoLKHPuNgsAvfEPEYba_idnopnXHa-iEHn7Dt8eS7wdYPDnYJlW3od7EIOvhJWe-VvVM72-_5ww5iNZyhY6NcgvPDXaD3h_u3u6di-fL4fHe7LAZa01xIIxkxhtYVaElb0nINjTBNJeuKCtJ0sjEdg45raQTjBKjoOm20McAFVVW1QFd_3CGGrxFSXnmbNDineghjWtG65pIyMU2zQJcH69h5WK-GaP3Ue_W_VvULfaBvHw</recordid><startdate>201306</startdate><enddate>201306</enddate><creator>Esteban, M</creator><creator>Castro, D M</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>201306</creationdate><title>Pharmacological treatment of lower urinary tract symptoms in men: implementation of recommendations in clinical practice</title><author>Esteban, M ; Castro, D M</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p141t-9f920ff143ec917075ce68f639431806b96fb2eb5c9f8250e18bbcfcffe581a33</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng ; spa</language><creationdate>2013</creationdate><topic>5-alpha Reductase Inhibitors - adverse effects</topic><topic>5-alpha Reductase Inhibitors - therapeutic use</topic><topic>Adrenergic alpha-Antagonists - adverse effects</topic><topic>Adrenergic alpha-Antagonists - therapeutic use</topic><topic>Algorithms</topic><topic>Deamino Arginine Vasopressin - adverse effects</topic><topic>Deamino Arginine Vasopressin - therapeutic use</topic><topic>Drug Interactions</topic><topic>Drug Therapy, Combination</topic><topic>Humans</topic><topic>Hyponatremia - chemically induced</topic><topic>Lower Urinary Tract Symptoms - classification</topic><topic>Lower Urinary Tract Symptoms - diagnosis</topic><topic>Lower Urinary Tract Symptoms - drug therapy</topic><topic>Male</topic><topic>Muscarinic Antagonists - adverse effects</topic><topic>Muscarinic Antagonists - therapeutic use</topic><topic>Prostatism - diagnosis</topic><topic>Prostatism - drug therapy</topic><topic>Prostatism - surgery</topic><topic>Severity of Illness Index</topic><topic>Sodium Potassium Chloride Symporter Inhibitors - adverse effects</topic><topic>Sodium Potassium Chloride Symporter Inhibitors - therapeutic use</topic><topic>Urinary Retention - chemically induced</topic><toplevel>online_resources</toplevel><creatorcontrib>Esteban, M</creatorcontrib><creatorcontrib>Castro, D M</creatorcontrib><creatorcontrib>comité científico</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>Actas urologicas españolas</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Esteban, M</au><au>Castro, D M</au><aucorp>comité científico</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Pharmacological treatment of lower urinary tract symptoms in men: implementation of recommendations in clinical practice</atitle><jtitle>Actas urologicas españolas</jtitle><addtitle>Actas Urol Esp</addtitle><date>2013-06</date><risdate>2013</risdate><volume>37</volume><issue>6</issue><spage>330</spage><epage>337</epage><pages>330-337</pages><eissn>1699-7980</eissn><abstract>Introducing a consensus on pharmacological treatment of male LUTs to be applied to Urology Primary Care. EVIDENCE COMPILATION: The consensus has been created by an expert committee based on the latest recommendations by the European and American Guides for male LUTs treatment. Also, a bibliographic review of the latest advances in the therapeutical approach to these patients has been carried out. Although the prevalence of both LUTs and overactive bladder is high, and its impact on the quality of life and social cost have been widely described, the number of patients treated is low. On the other hand, current clinical practice doesn't necessarily match the Guides and for this reason false perceptions of the available treatments circulate. For instance, men with storage LUTS are often treated inadequately with α-blockers or 5-α-reductase inhibitors due to underlying obstructive disorders. However, it is known that the incidence of real obstruction tends to be low. Current evidence, though limited, shows that antimuscarinic drugs may be used safely by men with LUTs, and are not associated with an increase in the prevalence of high urinary retention. We propose an algorithm for the management of male LUTs in which various levels of clinical evaluation are shown for a specific diagnose, as well as for choosing the most appropriate treatment.</abstract><cop>Spain</cop><pmid>22959516</pmid><doi>10.1016/j.acuro.2012.05.007</doi><tpages>8</tpages></addata></record>
fulltext fulltext
identifier EISSN: 1699-7980
ispartof Actas urologicas españolas, 2013-06, Vol.37 (6), p.330-337
issn 1699-7980
language eng ; spa
recordid cdi_proquest_miscellaneous_1445912824
source MEDLINE; Elsevier ScienceDirect Journals
subjects 5-alpha Reductase Inhibitors - adverse effects
5-alpha Reductase Inhibitors - therapeutic use
Adrenergic alpha-Antagonists - adverse effects
Adrenergic alpha-Antagonists - therapeutic use
Algorithms
Deamino Arginine Vasopressin - adverse effects
Deamino Arginine Vasopressin - therapeutic use
Drug Interactions
Drug Therapy, Combination
Humans
Hyponatremia - chemically induced
Lower Urinary Tract Symptoms - classification
Lower Urinary Tract Symptoms - diagnosis
Lower Urinary Tract Symptoms - drug therapy
Male
Muscarinic Antagonists - adverse effects
Muscarinic Antagonists - therapeutic use
Prostatism - diagnosis
Prostatism - drug therapy
Prostatism - surgery
Severity of Illness Index
Sodium Potassium Chloride Symporter Inhibitors - adverse effects
Sodium Potassium Chloride Symporter Inhibitors - therapeutic use
Urinary Retention - chemically induced
title Pharmacological treatment of lower urinary tract symptoms in men: implementation of recommendations in clinical practice
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-20T10%3A52%3A18IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Pharmacological%20treatment%20of%20lower%20urinary%20tract%20symptoms%20in%20men:%20implementation%20of%20recommendations%20in%20clinical%20practice&rft.jtitle=Actas%20urologicas%20espa%C3%B1olas&rft.au=Esteban,%20M&rft.aucorp=comit%C3%A9%20cient%C3%ADfico&rft.date=2013-06&rft.volume=37&rft.issue=6&rft.spage=330&rft.epage=337&rft.pages=330-337&rft.eissn=1699-7980&rft_id=info:doi/10.1016/j.acuro.2012.05.007&rft_dat=%3Cproquest_pubme%3E1445912824%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1445912824&rft_id=info:pmid/22959516&rfr_iscdi=true